Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
Curr Treat Options Oncol ; 22(10): 95, 2021 09 13.
Artigo em Inglês | MEDLINE | ID: mdl-34515857

RESUMO

OPINION STATEMENT: While emergency use is authorized for numerous COVID-19 vaccines and the high-risk population including cancer patients or those with immunosuppression due to disease or therapy is prioritized, data on this group's specific safety and efficacy of these vaccines remains limited. Safety data from clinical trials and population data may be extrapolated, and these vaccines may be used for cancer patients. However, concerns of efficacy due to the variable immune response in patients with active cancers undergoing active therapy and cancer survivors with chronic immunosuppression remain. The authors aim to discuss the current recommendations for use of COVID-19 vaccination in patients with cancer.


Assuntos
Vacinas contra COVID-19/efeitos adversos , Vacinas contra COVID-19/uso terapêutico , COVID-19/prevenção & controle , Neoplasias/imunologia , Vacinação/efeitos adversos , COVID-19/complicações , Humanos , Sistema Imunitário , Imunização , Hospedeiro Imunocomprometido , Terapia de Imunossupressão , Oncologia/normas , Neoplasias/complicações , Segurança do Paciente , Guias de Prática Clínica como Assunto , SARS-CoV-2 , Resultado do Tratamento
2.
SN Compr Clin Med ; 2(12): 2691-2701, 2020.
Artigo em Inglês | MEDLINE | ID: mdl-33251481

RESUMO

In the wake of the COVID-19 pandemic, due to reasons beyond control, health care workers have struggled to deliver treatment for the patients with cancer. The concern for otherwise healthy patients with curable cancers that require timely intervention or therapy is the risk of contracting COVID-19 may outweigh the benefits of cancer treatment. Lack of international guidelines leaves health care providers with a case-to-case approach for delivering optimal cancer care in the wake of the pandemic. Transition to telemedicine has somewhat bridged the gap for in-office visits, but there is a continuing challenge of delays in cancer screening or significant decline of new diagnoses of cancers due to the pandemic. We aim to propose a balance in risk from treatment delay versus risks from COVID-19 with emphasis on treatment modality (surgery, radiation, and systemic therapy) as well as supportive care for cancer patients, and therefore have reviewed the publications and recommendations from international societies and study groups available as of October 2020.

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA